EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cardiomyopathy in Patients With Acromegaly – Not Truly a Concern Anymore?

Peter Wolf iD, Luigi Maione iD, Peter Kamenický iD, Philippe Chanson iD

The Journal of Clinical Endocrinology & Metabolism · 16.09.2025 · 110 (10) · 2718-2728

DOI: 10.1210/clinem/dgaf338 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 09.06.2025. Verfasst von Peter Wolf und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical University of Vienna, Department of Internal Medicine III, Division of Endocrinology and Metabolism Vienna 1090, Austria. Hauptthemen laut MEDLINE: Acromegaly, Cardiomyopathies. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 161 Literaturangaben. Gefördert von: Austrian Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acromegaly is associated with increased mortality rates if not adequately treated. Cardiovascular and metabolic comorbidities are highly prevalent and have long been considered the main cause of death among patients with acromegaly. However, substantial advances in GH/IGF-I-lowering treatment, together with increased awareness and optimized management of other risk factors, have led to major improvements in mortality rates in the 2-3 past decades. Here, we review the effects of chronic excessive GH/IGF-I production and the successful treatment of this condition on relevant classical cardiovascular risk factors and on morphological and functional changes in the heart and discuss differences in reported prevalence rates over time according to different imaging methodologies used. Although morphological alterations (ie, myocardial hypertrophy as well as increased atrial and ventricular volumes) are common in patients with acromegaly, overt clinically relevant dysfunction is rare. Valvular cardiac disease and arrhythmia are also reviewed. Clinically relevant cardiomyopathy is currently less common than previously estimated. Recent epidemiological studies have shown that the risk of heart failure is comparable to that of the general population after adjusting for biochemical disease control and other risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyCardiomyopathiesHumansHuman Growth HormoneRisk FactorsPrevalenceInsulin-Like Growth Factor I

Stichwörter der Autor:innen

GHIGF-Iacromegalycardiomyopathycardiovascular riskheart

Substanzen

Human Growth HormoneInsulin-Like Growth Factor I

Autor:innen und Institutionen

  • Medical University of Vienna, Department of Internal Medicine III, Division of Endocrinology and Metabolism Vienna 1090, Austria.
  • Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse (HYPO), Assistance Publ…

ORCID-Profile: Peter Wolf, Luigi Maione, Peter Kamenický, Philippe Chanson

Förderung

  • Austrian Science Fund

Zitieren

APA

Wolf, P., Maione, L., Kamenický, P., & Chanson, P. (2025). Cardiomyopathy in Patients With Acromegaly – Not Truly a Concern Anymore?. The Journal of Clinical Endocrinology & Metabolism, 110(10), 2718-2728. https://doi.org/10.1210/clinem/dgaf338

Vancouver

Wolf P, Maione L, Kamenický P, Chanson P. Cardiomyopathy in Patients With Acromegaly – Not Truly a Concern Anymore?. The Journal of Clinical Endocrinology & Metabolism. 2025;110(10):2718-2728. doi:10.1210/clinem/dgaf338

BibTeX
@article{Wolf2025,
  author = {Wolf, Peter and Maione, Luigi and Kamenický, Peter and Chanson, Philippe},
  title = {Cardiomyopathy in Patients With Acromegaly – Not Truly a Concern Anymore?},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {10},
  pages = {2718--2728},
  doi = {10.1210/clinem/dgaf338}
}
Kostenlos starten →